Therapeutic Asset Ratings
130 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[225ac]-fpi-2068
Head and Neck Squamous Cell Carcinoma
AstraZeneca
P1
C
(37)
ai-061
Head and Neck Squamous Cell Carcinoma
OncoC4, Inc.
P1
C
(37)
Anti-Cd70-Car-T Cells
Head and Neck Squamous Cell Carcinoma
Zhejiang University
P1
C
(37)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes
Head and Neck Squamous Cell Carcinoma
Anusha Kalbasi
P1
C
(37)
Autologous, Engineered T Cells Targeting Tp53 R175H
Head and Neck Squamous Cell Carcinoma
AstraZeneca
P1
C
(37)
Azirkitug
Head and Neck Squamous Cell Carcinoma
AbbVie
P1
C
(37)
Bl-M24D1
Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(37)
Budigalimab
Head and Neck Squamous Cell Carcinoma
AbbVie
P1
C
(37)
Cadvec
Head and Neck Squamous Cell Carcinoma
Baylor College of Medicine
P1
C
(37)
cht101
Head and Neck Squamous Cell Carcinoma
Zhejiang University
P1
C
(37)
Clsp-1025
Head and Neck Squamous Cell Carcinoma
Clasp Therapeutics, Inc.
P1
C
(37)
Ctx-8371
Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
P1
C
(37)
Drug: Ibi3028
Head and Neck Squamous Cell Carcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(37)
Emunkitug
Head and Neck Squamous Cell Carcinoma
HiFiBiO Therapeutics
P1
C
(37)
Fpi-2053
Head and Neck Squamous Cell Carcinoma
AstraZeneca
P1
C
(37)
ft836
Head and Neck Squamous Cell Carcinoma
Fate Therapeutics
P1
C
(37)
[Ga-68]-PNT6555
Head and Neck Squamous Cell Carcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
C
(37)
hh160
Head and Neck Squamous Cell Carcinoma
Huahui Health
P1
C
(37)
Hryz-T101
Head and Neck Squamous Cell Carcinoma
HRYZ Biotech Co.
P1
C
(37)
Hryz-T101 Tcr-T Cell
Head and Neck Squamous Cell Carcinoma
HRYZ Biotech Co.
P1
C
(37)
ide034
Head and Neck Squamous Cell Carcinoma
IDEAYA Biosciences
P1
C
(37)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells
Head and Neck Squamous Cell Carcinoma
Anusha Kalbasi
P1
C
(37)
Immunoglobulin G1, anti-(human CC chemokine receptor CCR8) (human monoclonal CHS114 ?1-chain), disulfide with human monoclonal CHS114 ?-chain, dimer
Head and Neck Squamous Cell Carcinoma
Coherus Oncology, Inc.
P1
C
(37)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer
Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
P1
C
(37)
immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, OX40, CD134)], Homo sapiens monoclonal antibody
Head and Neck Squamous Cell Carcinoma
HiFiBiO Therapeutics
P1
C
(37)
Showing 76 to 100 of 130 assets
Previous
Page 4 of 6
Next